Lyndon Marc Evans

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7502078/publications.pdf

Version: 2024-02-01

97 papers	2,500 citations	172207 29 h-index	223531 46 g-index
100 all docs	100 docs citations	100 times ranked	2994 citing authors

#	Article	IF	Citations
1	Effects of HMG-CoA Reductase Inhibitors on Skeletal Muscle. Drug Safety, 2002, 25, 649-663.	1.4	184
2	Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health and Quality of Life Outcomes, 2013, 11, 90.	1.0	142
3	Drug Therapy in Obesity: A Review of Current and Emerging Treatments. Diabetes Therapy, 2020, 11, 1199-1216.	1.2	123
4	A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes, Obesity and Metabolism, 2011, 13, 677-684.	2.2	122
5	Association between diabetic eye disease and other complications of diabetes: Implications for care. A systematic review. Diabetes, Obesity and Metabolism, 2019, 21, 467-478.	2.2	110
6	Antigen Processing Defects in Cervical Carcinomas Limit the Presentation of a CTL Epitope from Human Papillomavirus 16 E6. Journal of Immunology, 2001, 167, 5420-5428.	0.4	101
7	The myotoxicity of statins. Current Opinion in Lipidology, 2002, 13, 415-420.	1.2	95
8	Cardiovascular and heart failure safety profile of vildagliptin: a metaâ€analysis of 17â€‰000 patients. Diabetes, Obesity and Metabolism, 2015, 17, 1085-1092.	2.2	89
9	Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21Â334 patients in the UK. ESC Heart Failure, 2019, 6, 280-290.	1.4	57
10	A Narrative Review of ChronicÂKidneyÂDisease in Clinical Practice: Current Challenges and Future Perspectives. Advances in Therapy, 2022, 39, 33-43.	1.3	57
11	Clinical use of insulin degludec. Diabetes Research and Clinical Practice, 2015, 109, 19-31.	1.1	56
12	SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice. Diabetes Therapy, 2018, 9, 1757-1773.	1.2	53
13	Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials. Diabetes Therapy, 2020, 11, 369-386.	1.2	48
14	Effects of insulin lispro and chronic vitamin C therapy on postprandial lipaemia, oxidative stress and endothelial function in patients with type 2 diabetes mellitus. European Journal of Clinical Investigation, 2003, 33, 231-238.	1.7	47
15	Realâ€World Associations of Reninâ€“Angiotensinâ€“Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With Newâ€Onset Chronic Kidney Disease or Heart Failure in the United Kingdom. Journal of the American Heart Association, 2019, 8, e012655.	1.6	44
16	Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?. Diabetes Therapy, 2020, 11, 2207-2219.	1.2	41
17	Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial. Nephrology Dialysis Transplantation, 2012, 27, 2255-2263.	0.4	40
18	Costâ€effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulinÂâ€“Âfrom the <scp>UK</scp> health care cost perspective. Diabetes, Obesity and Metabolism, 2014, 16, 366-375.	2.2	40

#	Article	IF	Citations
19	Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24â€week, randomized, openâ€label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (<scp>L</scp>anScape). Diabetes, Obesity and Metabolism, 2015, 17, 1133-1141.	2.2	39
20	Flexible insulin dosing improves health-related quality-of-life (HRQoL): a time trade-off survey. Journal of Medical Economics, 2013, 16, 1357-1365.	1.0	38
21	A Retrospective, Case-Note Survey of Type 2 Diabetes Patients Prescribed Incretin-Based Therapies in Clinical Practice. Diabetes Therapy, 2013, 4, 27-40.	1.2	37
22	Treatment choice, medication adherence and glycemic efficacy in people with type 2 diabetes: a UK clinical practice database study. BMJ Open Diabetes Research and Care, 2018, 6, e000512.	1.2	37
23	SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1câ€"Translating Evidence into Practice. Diabetes Therapy, 2019, 10, 1595-1622.	1.2	36
24	Understanding the interâ€relationship between improved glycaemic control, hypoglycaemia and weight change within a longâ€term economic model. Diabetes, Obesity and Metabolism, 2010, 12, 431-436.	2.2	34
25	Healthcare resource implications of hypoglycemia-related hospital admissions and inpatient hypoglycemia: retrospective record-linked cohort studies in England. BMJ Open Diabetes Research and Care, 2015, 3, e000057.	1.2	34
26	Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink. BMC Nephrology, 2018, 19, 211.	0.8	34
27	Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK. Journal of Medical Economics, 2015, 18, 56-68.	1.0	32
28	A comparison of healthâ€related quality of life (health utility) between insulin degludec and insulin glargine: a metaâ€analysis of phase 3 trials. Diabetes, Obesity and Metabolism, 2013, 15, 564-571.	2.2	30
29	Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes. Diabetes Therapy, 2020, 11, 37-52.	1.2	29
30	Descriptions of health states associated with increasing severity and frequency of hypoglycemia: a patient-level perspective. Patient Preference and Adherence, 2013, 7, 925.	0.8	28
31	Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus. Diabetes Therapy, 2017, 8, 275-291.	1.2	26
32	The future direction of cholesterol-lowering therapy. Current Opinion in Lipidology, 2002, 13, 663-669.	1.2	24
33	Estimating the impact of changes in HbA1c, body weight and insulin injection regimen on health related quality-of-life: a time trade off study. Health and Quality of Life Outcomes, 2016, 14, 13.	1.0	24
34	An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin. Journal of Medical Economics, 2018, 21, 340-347.	1.0	24
35	The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease. BMC Nephrology, 2019, 20, 31.	0.8	24
36	Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practiceâ€"a case-based evaluation. Journal of Medical Economics, 2015, 18, 96-105.	1.0	23

#	Article	IF	Citations
37	Clinical Safety and Tolerability of Vildagliptin â€“ Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance. European Endocrinology, 2017, 13, 68.	0.8	23
38	Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review. Diabetes, Obesity and Metabolism, 2022, 24, 377-390.	2.2	23
39	Sodium-Glucose Co-TransporterÂ2 (SGLT2) Inhibitors: Are They All the Same? A Narrative Review of Cardiovascular Outcome Trials. Diabetes Therapy, 2021, 12, 55-70.	1.2	22
40	Costs and Healthcare Resource Use Associated with Risk of Cardiovascular Morbidity in Patients with Chronic Kidney Disease: Evidence from a Systematic Literature Review. Advances in Therapy, 2021, 38, 994-1010.	1.3	22
41	Approach to assessing the economic impact of insulinâ€related hypoglycaemia using the novel Local Impact of Hypoglycaemia Tool. Diabetic Medicine, 2015, 32, 1156-1166.	1.2	21
42	Blood pressure and fasting lipid changes after 24 weeks’ treatment with vildagliptin: a pooled analysis in >2,000 previously drug-naïve patients with type 2 diabetes mellitus. Vascular Health and Risk Management, 2016, Volume 12, 337-340.	1.0	21
43	SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes. Diabetes Therapy, 2020, 11, 2757-2774.	1.2	20
44	Vaccinating Adolescents and Children Significantly Reduces COVID-19 Morbidity and Mortality across All Ages: A Population-Based Modeling Study Using the UK as an Example. Vaccines, 2021, 9, 1180.	2.1	18
45	Risk Prediction of the Diabetes Missing Million: Identifying Individuals at High Risk of Diabetes and Related Complications. Diabetes Therapy, 2021, 12, 87-105.	1.2	17
46	Managing glycaemia in older people with type 2 diabetes: <scp>A</scp> retrospective, primary careâ€based cohort study, with economic assessment of patient outcomes. Diabetes, Obesity and Metabolism, 2017, 19, 644-653.	2.2	16
47	Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse Î²-cell function in the GetGoal-M and GetGoal-S trials. Journal of Diabetes and Its Complications, 2016, 30, 1385-1392.	1.2	15
48	Are SGLT-2 Inhibitors the Future of Heart Failure Treatment? The EMPEROR-Preserved and EMPEROR-Reduced Trials. Diabetes Therapy, 2020, 11, 1925-1934.	1.2	15
49	Assessing the economic value of maintained improvements in Type 1 diabetes management, in terms of HbA_{1c}, weight and hypoglycaemic event incidence. Diabetic Medicine, 2018, 35, 557-566.	1.2	14
50	Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting. Diabetes Therapy, 2018, 9, 1919-1930.	1.2	14
51	Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies. Diabetes Therapy, 2020, 11, 2221-2235.	1.2	14
52	A look to the future in nonâ€alcoholic fatty liver disease: Are glucagonâ€like peptideâ€1 analogues or sodiumâ€glucose coâ€transporterâ€2 inhibitors the answer?. Diabetes, Obesity and Metabolism, 2020, 22, 2227-2240.	2.2	14
53	Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes. Drugs, 2020, 80, 147-165.	4.9	13
54	Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin. Diabetes Therapy, 2019, 10, 1793-1800.	1.2	11

#	Article	IF	Citations
55	Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors. Diabetes Therapy, 2022, 13, 241-250.	1.2	11
56	Haemolytic uraemic syndrome associated with OKT3. Transplant International, 1996, 9, 522-523.	0.8	10
57	Evaluation of Insulin Use and Value for Money in Type 2 Diabetes in the United Kingdom. Diabetes Therapy, 2013, 4, 51-66.	1.2	9
58	Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial. Advances in Therapy, 2020, 37, 2413-2426.	1.3	9
59	Pharmacological treatment for Type 2 diabetes integrating findings from cardiovascular outcome trials: an expert consensus in the UK. Diabetic Medicine, 2019, 36, 1063-1071.	1.2	8
60	Systematic literature review and network metaâ€analysis of sodiumâ€glucose coâ€transporter inhibitors vs metformin as addâ€on to insulin in type 1 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 39-50.	2.2	8
61	A populationâ€adjusted indirect comparison of cardiovascular benefits of onceâ€weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease. Endocrinology, Diabetes and Metabolism, 2021, 4, e00259.	1.0	8
62	Incorporating Cardioprotective Effects of Once-Weekly Semaglutide in Estimates of Health Benefits for Patients with Type 2 Diabetes. Diabetes, 2018, 67, .	0.3	7
63	The Population-Wide Risk-Benefit Profile of Extending the Primary COVID-19 Vaccine Course Compared with an mRNA Booster Dose Program. Vaccines, 2022, 10, 140.	2.1	7
64	Healthcare costs and hospitalizations in <scp>US</scp> patients with type 2 diabetes and cardiovascular disease: A retrospective database study (<scp>OFFSET</scp>). Diabetes, Obesity and Metabolism, 2022, 24, 1300-1309.	2.2	7
65	Lixisenatide as add-on therapy to basal insulin. Drug Design, Development and Therapy, 2013, 8, 25.	2.0	6
66	Diabetes and Novel Coronavirus Infection: Implications for Treatment. Diabetes Therapy, 2020, 11, 1915-1924.	1.2	6
67	Costâ€effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United Kingdom. Diabetes, Obesity and Metabolism, 2020, 22, 1047-1055.	2.2	6
68	An alternative approach to modelling <scp>HbA1c</scp> trajectories in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2017, 19, 628-634.	2.2	5
69	Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus. Diabetes Therapy, 2018, 9, 27-36.	1.2	5
70	Development of a health economic model to evaluate the potential benefits of optimal serum potassium management in patients with heart failure. Journal of Medical Economics, 2018, 21, 1172-1182.	1.0	5
71	What Next After Metformin? Thinking Beyond Glycaemia: Are SGLT2 Inhibitors the Answer?. Diabetes Therapy, 2019, 10, 1719-1731.	1.2	5
72	The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review. Diabetes Therapy, 2022, 13, 847-872.	1.2	5

#	Article	IF	Citations
73	Serum potassium variability as a predictor of clinical outcomes in patients with cardiorenal disease or diabetes: a retrospective UK database study. CKJ: Clinical Kidney Journal, 2022, 15, 758-770.	1.4	5
74	Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?. Diabetes Therapy, 2015, 6, 1-5.	1.2	4
75	Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective. Diabetes Therapy, 2016, 7, 809-823.	1.2	4
76	A systematic review of the safety of incretin-based therapies in type 2 diabetes. Expert Review of Endocrinology and Metabolism, 2016, 11, 217-232.	1.2	4
77	What Next After Metformin in Type 2 Diabetes? Selecting the Right Drug for the Right Patient. Diabetes Therapy, 2020, 11, 1381-1395.	1.2	4
78	Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice. Diabetes Therapy, 2022, 13, 225-240.	1.2	4
79	New Therapeutic Horizons in ChronicÂKidneyÂDisease: The Role of SGLT2 Inhibitors in Clinical Practice. Drugs, 2022, 82, 97-108.	4.9	4
80	Factors Predictive of Weight Gain and Implications for Modeling in Type 2 Diabetes Patients Initiating Metformin and Sulfonylurea Combination Therapy. Diabetes Therapy, 2015, 6, 495-507.	1.2	3
81	Clinical and costâ€“effectiveness of insulin degludec: from clinical trials to clinical practice. Journal of Comparative Effectiveness Research, 2015, 4, 279-286.	0.6	3
82	Hypoglycemia, diabetes therapies and driving categories in type 2 diabetes. Current Medical Research and Opinion, 2016, 32, 1005-1012.	0.9	3
83	Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK. Diabetes Therapy, 2017, 8, 1175-1185.	1.2	3
84	A Summary of 2018 and What Lies Ahead for Diabetes Therapy in 2019. Diabetes Therapy, 2019, 10, 1-3.	1.2	3
85	One Hundred Years of Insulin: Value Beyond Price in Type 2 Diabetes Mellitus. Diabetes Therapy, 2021, 12, 1593-1604.	1.2	3
86	Letter from the Editor. Diabetes Therapy, 2010, 1, 1-1.	1.2	2
87	Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors. Drugs, 2021, 81, 1243-1255.	4.9	2
88	Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently. Diabetes Therapy, 2022, 13, 889-911.	1.2	2
89	FP337RELATIONSHIP BETWEEN HYPERKALAEMIA AND DOWN-TITRATION OR DISCONTINUATION OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS IN UK PATIENTS WITH CKD. Nephrology Dialysis Transplantation, 2018, 33, i145-i145.	0.4	1
90	Living with Type 2 Diabetes: Patient Commentary in Response to the Paper â€˜SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practiceâ€™. Diabetes Therapy, 2018, 9, 1729-1732.	1.2	1

#	Article	IF	Citations
91	The Value of Insulin Degludec in Frail Older Adults with Type 2 Diabetes. Diabetes Therapy, 2021, 12, 2817-2826.	1.2	1
92	Factors Associated With Weight Gain and Hypoglycaemia and The Impact Upon Hospitalisation in Type 2 Diabetes Patients Managed With Metformin Plus Sulphonylurea. Value in Health, 2014, 17, A360.	0.1	0
93	Practical Approaches to Diabetes Care: An Introduction. Diabetes Therapy, 2016, 7, 377-377.	1.2	0
94	P1810The association between renin-angiotensin-aldosterone system inhibitors dose reduction and risk of mortality and major adverse cardiovascular events in heart failure patients. European Heart Journal, 2018, 39, .	1.0	0
95	FP371RECURRENT HYPERKALAEMIA AND ASSOCIATION WITH LENGTH-OF-STAY AND MORTALITY FOLLOWING HOSPITALISATION: REAL-WORLD EVIDENCE FROM UK PATIENTS WITH CKD. Nephrology Dialysis Transplantation, 2018, 33, i157-i157.	0.4	0
96	P5671Real-world dosing of renin-angiotensin-aldosterone system inhibitors in heart failure patients, and associations between hyperkalaemia and down-titration or discontinuation. European Heart Journal, 2018, 39, .	1.0	0
97	An update to: Pharmacological treatment for type 2 diabetes integrating findings from cardiovascular outcome trials: an expert consensus in the UK . Diabet Med 2019; 36: 1063â€“1071. Diabetic Medicine, 2020, 37, 1405-1407.	1.2	0